This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Clinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. This data can also provide guidance in terms of diversifying clinical trials to include different types of population demographics such as age, gender, race, ethnicity, or geographic location.
Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. When time is of the essence, like in a global pandemic, how do you scale trials internationally for success? Additionally, clinical trials are no longer confined to one country or region.
AI can help in speeding up various phases like target identification, molecule optimization, and pre-clinical testing, thereby reducing the cost and time to bring a drug to market. Faster Time-to-Market: AI-driven predictive maintenance can reduce machine downtime, ensuring smoother manufacturing processes and quicker product delivery.
Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. This allows the trial to achieve more precise results at the indication level through leveraging comprehensive information from across the globe. “I
In this edition, our CEO and co-founder, Ariel Katz, along with Regional VP of Trial Landscape, Ryan Brown, share their top predictions for 2025. Drug Policy There will be significant changes in clinical trials & drug development due to the Inflation Reduction Act.
The success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within a trial population helps ensure the safety and efficacy of drugs that reach the market.
The drug development process is known to be often expensive, lengthy, and full of trial and error before finding success. This not only ensures overall safety but also creates opportunities for better access equity throughout different regions and markets worldwide.
In November and December, several large pharmas held “AI Day” presentations featuring LLM applications for clinical trial data analysis. Aside from some very brief demos on code generation and literature searches, mentions of LLM applications in preclinical research were scarce. Most of the drug discovery examples were underwhelming.
Read Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial. R21, developed at the University of Oxford, was up to 80% effective in a small clinical trial of 450 children in Burkina Faso. ‘OK’ to start clinical trials. Fierce Biotech.
Read Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial. R21, developed at the University of Oxford, was up to 80% effective in a small clinical trial of 450 children in Burkina Faso. ‘OK’ to start clinical trials. Fierce Biotech.
How will AI impact clinical trials? DOLs will also increasingly turn back to in-person interactions, conferences, public speaking, and other direct means to voice their opinions and establish a more credible presence, moving away from digital platforms.” – Alexandra Moens, Senior Director of Product Marketing 4.
Expected Action Description of action Date Eudamed Module: Market Surveillance [E.U.] Completed development of the EUDAMED Market Surveillance module Q4 2023 Designation of E.U. policy, such as public registers, drafts, reflection papers, concept papers, and guidance documents expected into Q1 2024.
Breaking the Barriers: How Inaccurate Trial Records Are Delaying Drug Development and Limiting Diverse Patient Populations In an October 2023 report , BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical trials.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content